High-Grade Serous Ovarian Cancers Derived − Transformation to Promote Formation of Fallopian Tube Cyclin E 1 Deregulation Occurs Early in Secretory Cell

The fallopian tube is now generally considered the dominant site of origin for high-grade serous ovarian carcinoma. However, the molecular pathogenesis of fallopian tube-derived serous carcinomas is poorly understood and there are few experimental studies examining the transformation of human fallopian tube cells. Prompted by recent genomic analyses that identified cyclin E1 (CCNE1) gene amplification as a candidate oncogenic driver in high-grade serous ovarian carcinoma, we evaluated the functional role of cyclin E1 in serous carcinogenesis. Cyclin E1 was expressed in earlyand late-stage human tumor samples. In primary human fallopian tube secretory epithelial cells, cyclin E1 expression imparted malignant characteristics to untransformed cells if p53 was compromised, promoting an accumulation of DNA damage and altered transcription of DNA damage response genes related to DNA replication stress. Together, our findings corroborate the hypothesis that cyclin E1 dysregulation acts to drive malignant transformation in fallopian tube secretory cells that are the site of origin of high-grade serous ovarian carcinomas. Cancer Res; 74(4); 1141–52. 2013 AACR.

[1]  I. Shih,et al.  Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. , 2014, Annual review of pathology.

[2]  R. Drapkin,et al.  Coming into focus: the nonovarian origins of ovarian cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  T. Helleday,et al.  Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress , 2013, Oncogene.

[4]  Maya Raghunandan,et al.  FANCD2 regulates BLM complex functions independently of FANCI to promote replication fork recovery , 2013, Nucleic acids research.

[5]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[6]  I. Shih,et al.  Rsf‐1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development , 2013, The Journal of pathology.

[7]  R. Drapkin,et al.  Primary culture and immortalization of human fallopian tube secretory epithelial cells , 2012, Nature Protocols.

[8]  Hong Wu,et al.  A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. , 2012, Cancer cell.

[9]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[10]  G. Mills,et al.  LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients , 2012, PLoS genetics.

[11]  Joe W. Gray,et al.  Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome , 2012, PloS one.

[12]  M. Rosner,et al.  An integrated view of cyclin E function and regulation , 2012, Cell cycle.

[13]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[14]  B. Kerem,et al.  Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development , 2011, Cell.

[15]  R. Drapkin,et al.  Modeling high-grade serous ovarian carcinogenesis from the fallopian tube , 2011, Proceedings of the National Academy of Sciences.

[16]  D. Ginsberg,et al.  miR-15 and miR-16 Are Direct Transcriptional Targets of E2F1 that Limit E2F-Induced Proliferation by Targeting Cyclin E , 2011, Molecular Cancer Research.

[17]  Kylie L. Gorringe,et al.  Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer , 2010, PloS one.

[18]  David D. L. Bowtell,et al.  The genesis and evolution of high-grade serous ovarian cancer , 2010, Nature Reviews Cancer.

[19]  Kylie L. Gorringe,et al.  Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer , 2010, PloS one.

[20]  G. Ning,et al.  A Pathologist's Road Map to Benign, Precancerous, and Malignant Intraepithelial Proliferations in the Fallopian Tube , 2010, Advances in anatomic pathology.

[21]  A. Składanowski,et al.  H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy , 2010, Journal of nucleic acids.

[22]  K. Hunt,et al.  Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. , 2010, Cancer research.

[23]  Kentaro Nakayama,et al.  Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer , 2010, Cancer.

[24]  I. Shih,et al.  Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase , 2010, Modern Pathology.

[25]  M. Hirsch,et al.  Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. , 2009, Gynecologic oncology.

[26]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[27]  R. Drapkin,et al.  Ovarian Cancer Pathogenesis: A Model in Evolution , 2009, Journal of oncology.

[28]  Joshy George,et al.  Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.

[29]  Jesse D. Martinez,et al.  Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. , 2008, Neoplasia.

[30]  R. Drapkin,et al.  Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[31]  B. Clurman,et al.  p53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability , 2007, Oncogene.

[32]  D. Albertson,et al.  DNA profiling of primary serous ovarian and Fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation‐dependent probe amplification , 2007, The Journal of pathology.

[33]  E. Dmitrovsky,et al.  Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas , 2007, Proceedings of the National Academy of Sciences.

[34]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[35]  J. Garber,et al.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube , 2007 .

[36]  S. Reed,et al.  Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland , 2006, Oncogene.

[37]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[38]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[39]  James M. Roberts,et al.  A mouse model for cyclin E-dependent genetic instability and tumorigenesis. , 2005, Cancer cell.

[40]  Ajay N. Jain,et al.  Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in Fallopian tube carcinoma , 2003, Oncogene.

[41]  B. Stewart,et al.  World Cancer Report , 2003 .

[42]  B. Clurman,et al.  p53 and p21 Form an Inducible Barrier that Protects Cells against Cyclin E-cdk2 Deregulation , 2002, Current Biology.

[43]  P. V. van Diest,et al.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.

[44]  Rochelle L. Garcia,et al.  Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. , 2001, Gynecologic oncology.

[45]  S. Reed,et al.  Deregulated cyclin E induces chromosome instability , 1999, Nature.

[46]  L. Johnson,et al.  Effects of Phosphorylation of Threonine 160 on Cyclin-dependent Kinase 2 Structure and Activity* , 1999, The Journal of Biological Chemistry.

[47]  W. Hahn,et al.  Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Bortner,et al.  Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E , 1997, Molecular and cellular biology.

[49]  Melanie M. Choe,et al.  The comet assay: a method to measure DNA damage in individual cells , 2006, Nature Protocols.